Emergent Biosolutions Inc. (NYSE:EBS) Receives $12.00 Average Price Target from Brokerages

Emergent Biosolutions Inc. (NYSE:EBS) has been given an average recommendation of “Hold” by the five analysts that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $12.00.

EBS has been the subject of several recent research reports. UBS Group reiterated a “buy” rating on shares of Emergent Biosolutions in a research report on Tuesday, June 2nd. Benchmark restated a “buy” rating on shares of Emergent Biosolutions in a research report on Tuesday, June 2nd. Finally, Weiss Ratings lowered shares of Emergent Biosolutions from a “sell (d)” rating to a “sell (d-)” rating in a report on Monday, May 11th.

Emergent Biosolutions Stock Performance

Shares of EBS opened at $7.28 on Wednesday. The stock has a 50 day moving average of $8.16 and a 200 day moving average of $9.16. The company has a market capitalization of $375.80 million, a price-to-earnings ratio of -26.01 and a beta of 2.34. Emergent Biosolutions has a 12 month low of $5.61 and a 12 month high of $14.06. The company has a current ratio of 4.29, a quick ratio of 2.08 and a debt-to-equity ratio of 1.10.

Emergent Biosolutions (NYSE:EBS) last announced its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $0.21 EPS for the quarter, topping the consensus estimate of ($0.25) by $0.46. Emergent Biosolutions had a negative net margin of 1.27% and a positive return on equity of 10.76%. The business had revenue of $156.10 million for the quarter, compared to analyst estimates of $145.00 million.

Insider Transactions at Emergent Biosolutions

In related news, Director Kathryn C. Zoon sold 17,202 shares of the company’s stock in a transaction on Friday, May 1st. The shares were sold at an average price of $8.40, for a total value of $144,496.80. Following the completion of the transaction, the director directly owned 79,941 shares in the company, valued at approximately $671,504.40. The trade was a 17.71% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Paul Anthony Williams sold 3,000 shares of the stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $8.40, for a total value of $25,200.00. Following the completion of the transaction, the senior vice president directly owned 159,098 shares in the company, valued at approximately $1,336,423.20. This represents a 1.85% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 64,925 shares of company stock valued at $543,512. Corporate insiders own 6.00% of the company’s stock.

Hedge Funds Weigh In On Emergent Biosolutions

Institutional investors have recently modified their holdings of the company. Legal & General Group Plc bought a new position in shares of Emergent Biosolutions during the second quarter valued at about $31,000. Torren Management LLC bought a new stake in shares of Emergent Biosolutions in the 4th quarter worth approximately $37,000. CANADA LIFE ASSURANCE Co purchased a new position in shares of Emergent Biosolutions during the fourth quarter valued at approximately $45,000. Raymond James Financial Inc. bought a new position in shares of Emergent Biosolutions during the second quarter valued at approximately $53,000. Finally, Farther Finance Advisors LLC raised its holdings in shares of Emergent Biosolutions by 361.3% during the fourth quarter. Farther Finance Advisors LLC now owns 6,163 shares of the biopharmaceutical company’s stock valued at $76,000 after acquiring an additional 4,827 shares in the last quarter. 78.40% of the stock is currently owned by institutional investors.

About Emergent Biosolutions

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.